Safety Assessment of Novel Respiratory Delivery Systems: Lessons from the Exubera® Development Program
Background
Non-traditional endpoints
Novel interactions/DDIs
FDA guidance
-
Contractor Management -
Cold Chain Management -
Rolling Out a New Cold Chain Solution to Maximise Validation and Process Efficiency -
Optimising the Vaccine Supply Chain -
Amgen Continuous Process Improvements in the Cold Chain -
BHC- Product Supply: Pipeline Transparency & Risk Asssessment -
Recent Developments in Optimised Forecast Accuracy, Sales and Operations Planning at Merck Serono -
Drug Discovery and the Market Today Part 4: Developing Amorphous Forms -
Drug Discovery and the Market Today Part 5: Considering Genotoxic and Carcinogenic Impurities -
Drug Discovery and the Market Today: Video Exclusive with Dr. David Elder, GSK
You Should Check Out:
* = required.
Not a member yet? Sign up
Events of Interest
-
Adverse Event Reporting Online Training Course 2011
August 3, 2011
Register Now -
Exploring Challenges and Opportunities in Predictive Safety Tools: Trends from Industry-Wide Surveys
January 13, 2012
Register Now -
Global HTA and CER Forum 2011
August 31, 2011
Register Now -
hESC derived Cytiva™ Cardiomyocytes for Drug Safety Testing
March 28, 2012
Register Now




Not a member? Sign Up
Reasons for Joining
Address your challenges through knowledge sharing with peers from our global network of specialists.
Benchmark your business initiatives with the who's who in the field.
Hear from industry pioneers how to maximize ROI in today's challenging economy.
And best of all It's FREE!